DaVita
DVA
$176.78
-2.01%
DaVita Inc. is one of the largest providers of kidney dialysis and related laboratory services in the United States, operating over 3,200 outpatient facilities worldwide and treating roughly 300,000 patients annually, with the vast majority of revenue generated domestically. The company holds approximately 35% US market share in dialysis, making it one half of a durable duopoly alongside Fresenius Medical Care, and its economics are uniquely driven by a payer mix in which government programs (primarily Medicare) account for about two-thirds of US sales while commercial insurers — representing only ~10% of patients — generate nearly all US dialysis profit. The current investor narrative centers on whether DaVita can sustain the margin expansion and earnings momentum it demonstrated through mid-2026, when quarterly EPS surged to $4.10 and net income reached $265 million, even as the stock suffered a violent ~24% three-month drawdown following its August peak. Debates now hinge on commercial reimbursement rate trends, the durability of cost-per-treatment discipline, the aggressive share repurchase program that has shrunk the diluted share count from ~88 million to ~66 million, and the leverage profile that leaves the equity technically insolvent on a book basis (negative equity) despite robust cash generation.…
DVA
DaVita
$176.78
Related headlines
Investment Opinion: Should I buy DVA Today?
Based on the synthesis of valuation, growth, and analyst sentiment, DaVita earns a Hold rating with a bullish tilt. The core thesis is that the company's deep value (forward P/E of 10.4x) and strong free cash flow ($1.61 billion TTM) are offset by significant leverage and reimbursement risks. The analyst consensus rating of 'Buy' (mean 2.375) and average target price of $219.86 suggest 23% upside, but the recent 24% drawdown and high short interest warrant caution.
Supporting evidence includes: 1) Revenue growth of 5.2% year-over-year in Q2 2026, driven by volume and rate increases; 2) Operating margin expansion to 16.1% from 15.9% a year ago, indicating cost discipline; 3) Free cash flow yield of 16.4%, which supports continued buybacks and debt reduction; and 4) The forward P/E of 10.4x is well below the healthcare sector average of ~15-20x, suggesting undervaluation. Additionally, the company has reduced its diluted share count by 25% in two quarters, boosting EPS.
Key risks that could invalidate the thesis include: 1) A change in Medicare reimbursement rates that compresses margins; 2) Loss of commercial contracts or pricing pressure from insurers; and 3) A liquidity crisis due to negative equity and high debt. The rating would upgrade to Buy if the stock sustains a breakout above $200 and commercial reimbursement trends remain stable, or downgrade to Sell if revenue growth decelerates below 3% or if free cash flow turns negative. Relative to its history and peers, DaVita appears undervalued on a cash flow basis, but the negative equity and regulatory overhang justify a cautious stance.
Sign up to view all
DVA 12-Month Price Forecast
DaVita presents a mixed picture: deep value and strong cash flow are offset by significant leverage and reimbursement risks. The analyst consensus is bullish with a $219.86 target, but the recent 24% drawdown and high short interest indicate market skepticism. The base case (55% probability) sees the stock trading in the $200-230 range, assuming stable reimbursement and continued buybacks. A break above $230 would require sustained margin expansion and positive regulatory news, while a drop below $165 could occur if reimbursement pressures mount. I would upgrade to bullish if the company demonstrates consistent commercial pricing power and reduces debt, and downgrade to bearish if free cash flow declines or leverage increases.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on DaVita's 12-month outlook, with a consensus price target around $219.86 and implied upside of +24.4% versus the current price.
Average Target
$219.86
0 analysts
Implied Upside
+24.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$165 - $270
Analyst target range
Drowning in data?
Find the real signal!
Bulls vs Bears: DVA Investment Factors
The bull case for DaVita rests on its deep value valuation, robust free cash flow, and aggressive share buybacks that have reduced the share count by 25% in two quarters. The bear case highlights the company's negative equity, high leverage, and dependence on commercial reimbursement, which is a concentrated profit driver. The recent 24% drawdown and high short interest suggest market skepticism about the sustainability of earnings growth. The most critical tension is whether DaVita can maintain its commercial pricing power and cost discipline to justify the optimistic analyst targets, or if reimbursement pressures and leverage will cap upside. Currently, the bull evidence appears stronger given the cash flow generation and analyst consensus, but the risks are substantial.
Bullish
- Deep Value Valuation: DaVita trades at a trailing P/E of 11.7x and a forward P/E of 10.4x, well below the S&P 500 average of ~20x. The PEG ratio is negative due to trailing earnings distortions, but the forward earnings multiple suggests the market is pricing in minimal growth despite the company's dominant market position.
- Strong Free Cash Flow Generation: The company generated $1.61 billion in trailing twelve-month free cash flow, representing a 16.4% FCF yield on the current market cap of $9.78 billion. This robust cash generation funds aggressive share repurchases and debt reduction.
- Aggressive Share Buybacks: Diluted shares outstanding have plummeted from 88.1 million in Q4 2025 to 66.1 million in Q2 2026, a 25% reduction in just two quarters. This buyback activity significantly boosts earnings per share and returns capital to shareholders.
- Improving Profitability Metrics: Q2 2026 EPS surged to $4.10, up 59% year-over-year from $2.58 in Q2 2025. Net income reached $265 million, and the operating margin expanded to 16.1% from 15.9% a year earlier, showcasing operational leverage.
Bearish
- Negative Equity and High Leverage: DaVita has negative shareholders' equity, with a debt-to-equity ratio of -23.1 and a price-to-book ratio of -15.0. This indicates that liabilities exceed assets, leaving the equity technically insolvent on a book basis and vulnerable to financial distress.
- Recent Sharp Drawdown: The stock has fallen 23.9% over the past three months, from a high of $247.49 to $178.69, significantly underperforming the S&P 500's 3.3% gain. This recent weakness may signal underlying issues or a shift in investor sentiment.
- Payer Mix Concentration Risk: Approximately two-thirds of US sales come from government payers (primarily Medicare), which reimburse at lower rates. Commercial insurers, representing only 10% of patients, generate nearly all profits, making earnings highly sensitive to any changes in commercial reimbursement or patient mix.
- High Short Interest: The short ratio stands at 7.15, indicating that it would take over a week for short sellers to cover their positions based on average trading volume. This high short interest reflects persistent bearish sentiment and could lead to volatility.
DVA Technical Analysis
Beta
0.80
0.80x market volatility
Max Drawdown
-27.9%
Largest decline past year
52-Week Range
$101-$247
Price range past year
Annual Return
+34.9%
Cumulative gain past year
| Period | DVA Return | S&P 500 |
|---|---|---|
| 1m | -3.9% | +0.9% |
| 3m | -23.0% | +3.4% |
| 6m | +17.8% | +14.4% |
| 1y | +34.9% | +16.2% |
| ytd | +54.4% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DVA Fundamental Analysis
Quarterly Revenue
$3.6B
2026-06
Revenue YoY Growth
+5.2%
YoY Comparison
Gross Margin
32.7%
Latest Quarter
Free Cash Flow
$1.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DVA Overvalued?
PE
11.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 8x~19x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.1x
Enterprise Value Multiple
Investment Risk Disclosure
DaVita's financial structure presents significant risks: the company operates with negative shareholders' equity, as reflected in a debt-to-equity ratio of -23.1 and a price-to-book ratio of -15.0. This means liabilities exceed assets, leaving little cushion for adverse events. Additionally, the company carries substantial debt, with interest expense of $146 million in Q2 2026 alone, which consumes a large portion of operating income. The current ratio of 1.29 indicates adequate short-term liquidity, but the heavy debt load and negative equity make the company vulnerable to rising interest rates or a downturn in cash flow.
Market and competitive risks are pronounced. DaVita faces intense regulatory scrutiny over dialysis reimbursement rates, as government payers account for two-thirds of US sales. Any changes to Medicare reimbursement could severely impact revenue. The company also operates in a duopoly with Fresenius, but competition for commercial patients is fierce. The stock's beta of 0.83 suggests lower volatility than the market, but the recent 24% drawdown shows it is not immune to sharp corrections. High short interest (short ratio 7.15) indicates that many investors are betting against the stock, which could exacerbate downward moves if negative news emerges.
The worst-case scenario for DaVita would involve a combination of reimbursement cuts, loss of commercial contracts, and a liquidity crunch. If commercial insurers reduce coverage or negotiate lower rates, profits could plummet since commercial patients generate nearly all US dialysis profits. A decline to the 52-week low of $101 would represent a 43% loss from the current price of $178.69. The analyst low target of $165 implies a 7.7% downside, but in a severe bear case, the stock could retest its 52-week low, especially if earnings disappoint or leverage concerns intensify. Investors could lose 43% in such an adverse scenario.
FAQ
The key risks include: 1) Financial risk: negative equity and high debt (debt-to-equity of -23.1) could lead to liquidity issues if cash flow declines; 2) Regulatory risk: two-thirds of US sales come from government payers, and any cuts to Medicare reimbursement could severely impact revenue; 3) Competitive risk: dependence on commercial insurers for nearly all profits means losing a major contract could be devastating; 4) Market risk: high short interest (7.15) and a recent 24% drawdown indicate negative sentiment that could persist. These risks are ranked from most to least severe, with financial and regulatory risks being the most critical.
Our 12-month forecast has three scenarios: Bull case (25% probability) targets $240-270, driven by earnings beats and favorable reimbursement; Base case (55% probability) targets $200-230, assuming steady execution and stable margins; Bear case (20% probability) targets $140-165, if reimbursement pressures intensify or leverage concerns mount. The base case is most likely, aligning with the analyst average target of $219.86. The key assumption is that commercial reimbursement rates remain stable and the company continues its buyback program. However, if Medicare reimbursement cuts occur, the bear case could materialize.
DaVita appears undervalued on most metrics. Its trailing P/E is 11.7x and forward P/E is 10.4x, compared to the S&P 500's ~20x. The price-to-sales ratio is 0.72, and EV/EBITDA is 9.1x, both relatively low. The free cash flow yield of 16.4% is attractive. However, the negative price-to-book ratio (-15.0) reflects the company's negative equity, which is a red flag. The market seems to be pricing in concerns about leverage and reimbursement risks, which may be overdone if the company continues to generate strong cash flow. Relative to its own history, the stock is trading at a discount, but the risks justify some discount.
DaVita could be a good buy for value-oriented investors who can tolerate risk. The stock trades at a forward P/E of 10.4x, well below the market average, and offers a free cash flow yield of 16.4%. Analysts have a 'Buy' consensus with an average target of $219.86, implying 23% upside. However, the company has negative equity and high leverage, and its profits are heavily dependent on commercial reimbursement, which is a regulatory risk. The recent 24% drawdown and high short interest (7.15) suggest caution. For those with a long-term horizon and a stomach for volatility, DVA could be a value play, but it is not without significant risks.
DaVita is more suitable for long-term investment (minimum 2-3 years) given its stable cash flows and dominant market position, but it requires patience due to regulatory and leverage risks. The stock has a beta of 0.83, indicating lower volatility than the market, but it has experienced a 24% drawdown in three months, so short-term trading is risky. The company pays no dividend, so returns depend on capital appreciation and buybacks. Earnings visibility is moderate, with analysts estimating EPS of $18.12 for the next fiscal year. Long-term investors can benefit from the company's cash generation and potential multiple expansion, but they must monitor reimbursement changes and debt levels closely.